U.S. Lawmakers Demand Scrutiny of TikTok-ByteDance Deal Amid National Security Concerns 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
Toyota Recalls 162,000 Tundra Vehicles in U.S. Over Multimedia Display Issue 
Ryanair Profit Slumps in Q3 After Italy Antitrust Fine Despite Revenue Growth 
Shell Plc Downgraded by RBC as Market Headwinds Pressure Valuation 
Delta Air Lines Operates Reduced Flight Schedule as Winter Storm Disrupts U.S. Travel 
LVMH Succession Uncertainty Raises Governance Concerns Among Shareholders 
Baker Hughes Reports 11% Rise in Q4 Adjusted Profit Driven by LNG Demand 
NTSB Opens Investigation Into Waymo Robotaxis After School Bus Safety Violations in Texas 
FCC Chairman Raises Competition Concerns Over Netflix–Warner Bros. Discovery Deal 
Trump Lawsuit Against JPMorgan Signals Rising Tensions Between Wall Street and the White House 
Embraer Targets Growth as Regional Jet Demand Surges Post-Pandemic 
Hermès Menswear Marks Historic Transition as Véronique Nichanian Bids Farewell in Paris 
Intel Stock Slides Despite Earnings Beat as Weak Q1 Outlook Raises Concerns 
CN Energy Group Inc. Stock Slides After Nasdaq Delisting Notice Over Bid Price Rule 
NEW YORK and SAN DIEGO, May 12, 2017 -- Wolf Haldenstein Adler Freeman & Herz LLP announces that a class action lawsuit has been filed against ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (Nasdaq:IMUC) in the United States District Court for the Central District of California on behalf of purchasers of ImmunoCellular securities from May 1, 2012 through December 11, 2013, inclusive (the “Class Period”).
Investors who have incurred losses in shares against ImmunoCellular Therapeutics, Ltd. are urged to contact the firm immediately at [email protected] or (800) 575-0735 or (212) 545-4774. You may obtain additional information concerning the action on our website, www.whafh.com.
If you suffered a loss in the shares of ImmunoCellular Therapeutics, Ltd., and would like to assist with the litigation process as a lead plaintiff, you may, no later than June 30, 2017, request that the Court appoint you lead plaintiff of the proposed class.
The filed Complaint alleges that that Defendants made false and misleading statements and/or failed to disclose that ImmunoCellular retained Lidingo Holdings, LLC to publish promotional articles designed to unlawfully promote ImmunoCellular, which led the market to believe that ImmunoCellular’s clinical studies for its product candidate ICT-107 was going well.
On April 10, 2017, the Securities and Exchange Commission (SEC) announced enforcement actions against ImmunoCellular, as well as other individuals and entities, for engaging in stock promotion schemes.
Wolf Haldenstein has extensive experience in the prosecution of securities class actions and derivative litigation in state and federal trial and appellate courts across the country. The firm has attorneys in various practice areas; and offices in New York, Chicago and San Diego. The reputation and expertise of this firm in shareholder and other class litigation has been repeatedly recognized by the courts, which have appointed it to major positions in complex securities multi-district and consolidated litigation.
If you wish to discuss this action or have any questions regarding your rights and interests in this case, please immediately contact Wolf Haldenstein by telephone at (800) 575-0735, via e-mail at [email protected], or visit our website at www.whafh.com.
## Follow the firm and learn about newly filed cases on Twitter and Facebook. ##
Attorney Advertising. Prior results do not guarantee or predict a similar outcome.
Contact: Wolf Haldenstein Adler Freeman & Herz LLP Kevin Cooper, Esq. Gregory Stone, Director of Case and Financial Analysis Email: [email protected], [email protected] or [email protected] Tel: (800) 575-0735 or (212) 545-4774
